

AROA BIOSURGERY INVITE TO INVESTOR WEBINAR

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, AROA' or the 'Company') is pleased to announce it will hold an investor webinar with CEO Brian Ward and CFO James Agnew on **Tuesday 3 February, at 9 AM AEDT**.

A business update will be released pre-market on the same day. The webinar will provide further commentary on the topics covered in that announcement, including:

- Symphony™ and US Medicare reimbursement update
- Recently published clinical data from the ongoing MASTRR study

Investors and interested parties can register to attend the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_8DdMh049TXu9mIM3kQGRBw

Questions can be submitted before the webinar to investor@aroa.com or during the webinar using the Q&A function on Zoom.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com

Contact

investor@aroa.com